Mycosis Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Mycosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Phase 2

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Mycosis FungoidesLymphomatoid PapulosisSezary Syndrome
Memorial Sloan Kettering Cancer Center58 enrolled8 locationsNCT03587844
Recruiting
Phase 3

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Mycosis FungoidesCutaneous T Cell LymphomaCTCL+1 more
Soligenix80 enrolled17 locationsNCT06470451
Recruiting

Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis

Coccidioidomycosis
National Institute of Allergy and Infectious Diseases (NIAID)400 enrolled1 locationNCT02190266
Recruiting

Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota

DysbiosisHPVMycosis+5 more
Centre National de la Recherche Scientifique, France300 enrolled1 locationNCT07199998
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Mycosis FungoidesLymphomatoid Papulosis
M.D. Anderson Cancer Center100 enrolled1 locationNCT06207812
Recruiting
Phase 3

Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis

Nail PsoriasisNail DamageMycosis
Wooshin Labottach Co., Ltd.72 enrolled1 locationNCT07029516
Recruiting
Phase 2

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Mycosis Fungoides
M.D. Anderson Cancer Center30 enrolled1 locationNCT05357794
Recruiting
Phase 2

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Cutaneous T Cell LymphomaFungoides Mycosis Sezary Syndrome
University of Michigan Rogel Cancer Center23 enrolled1 locationNCT05956041
Recruiting

Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value

Pulmonary Mucormycosis
University Hospital, Strasbourg, France80 enrolled1 locationNCT07339800
Recruiting

Biomarkers for Invasive Mucormycosis

Mucorales InfectionMucormycosis
University Hospital, Lille100 enrolled1 locationNCT05406037
Recruiting

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T-Cell Lymphoma/Sezary Syndrome
Fondazione Italiana Linfomi - ETS400 enrolled18 locationsNCT06588868
Recruiting
Phase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658
Recruiting
Phase 2

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

Mycosis FungoidesLocalized Skin Lesion
M.D. Anderson Cancer Center50 enrolled1 locationNCT03398161
Recruiting

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Non-Hodgkin's LymphomaMycosis Fungoides
Stanford University2,000 enrolled13 locationsNCT02848274
Recruiting
Phase 2

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8+5 more
City of Hope Medical Center34 enrolled3 locationsNCT04930653
Recruiting
Phase 2

Photopheresis in Early-stage Mycosis Fungoides

Mycosis FungoidesCutaneous T Cell Lymphoma
Columbia University74 enrolled1 locationNCT05680558
Recruiting

Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance

Mycosis FungoidesSezary Syndrome
Kyowa Kirin Co., Ltd.15 enrolled6 locationsNCT07132567
Recruiting

Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

Mucormycosis in Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China60 enrolled9 locationsNCT07185503
Recruiting

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

Recurrent Mycosis FungoidesRecurrent Sezary SyndromeRefractory Mycosis Fungoides+6 more
City of Hope Medical Center100 enrolled10 locationsNCT07003100